High-risk advanced hematological disease(leukemia and malignant lymphoma in non-remission, MDS with more than 20% of blast, and relapsed disease after allogeneic transplantation)
Conditions
Interventions
Sponsors
Division of Hematology, Saitama Medical Center, Jichi Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients who do not have an available HLA-matched or one locus-mismatched related donor. 2.Patients who have a two- or three-locus-mismatched haploidentical related donor in good condition.(This donor should precede an HLA-matched or one locus-mismatched related donor accoridng to the disease status.) 3.Patients who do not have an HLA-matched or one allele-mismatched unrelated donor, or patients whose disease status preclude time-consuming donor coordination. 4.Patients with high-risk advanced hematological disease. Leukemia and malignant lymphoma in non-remission, MDS with more than 20% of blast, and relapsed disease after allogeneic transplantation are included in high-risk group. 5.Patients who are 16 to 70 years old 6.Patients in performance status of 0 or 1. 7.Patients whose major organ functions are preserved.
Exclusion criteria
Exclusion criteria: 1.Patients with poorly controlled active infection. 2.Patients with coexistence of malignancy. 3.Patients who are pregnant or nursing. 4.Patients with serious mental disorder. 5.Patients with HIV antibody positive. 6.Patients who are allergic to drugs used in conditioning regimen or GVHD prophylaxis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival rate at 60 days after transplantation with the engraftment of donor cells and without grade III-IV GVHD | — |
Countries
Japan
Contacts
Public ContactShinichi Kako
Saitama Medical Center, Jichi Medical University Division of Hematology
Outcome results
None listed